R&D
Vanan is ably supported by an exclusive R&D facility in a 55,000 sq. ft with its focus on innovative product development.
The dedicated R&D has always strived towards expanding its capabilities to develop breakthrough technologies. There is a constant endeavor to enhance and/or maximize therapeutic value of the available formulations.
The state-of-the-art R&D facility has Formulation Development Laboratory, Analytical Development Laboratory and Synthesis Laboratory. These laboratories are fully equipped with state-of-the-art Pilot Scale Equipment, Sophisticated Analytical Instruments and Walk-in Stability Chambers for conducting Stability Studies as per ICH Guideline and has been accredited by DSIR (Directorate of Scientific & Industrial Research, India).
With a good team of experienced and well motivated scientists, fully equipped laboratory, stringent conformity to quality and documentation, the company has been able to introduce new innovative products from time to time with enhanced product efficacy which have achieved market acceptability, spiraling the growth of the corporate.
Owing to the focus on bringing innovative products to the global market, the R&D function is being managed as a strategic business unit. The objective is towards developing innovative products for new age therapies. The company is proud to have developed many product formulations which are patented across the globe.
R&D ACHIEVEMENT
One of the most significant achievements of our R&D Division is the successful launch of a patented formulation of Sodium Fusidate in a cream matrix of Biochitoderm, a dermatological, topical antibacterial cream which is first-of-its-kind in the world, utilizing a novel technology platform. The company is proud to have achieved around 18 patents across 10 countries and 12 more patent applications are under examination of the product. The medical profession’s acceptance of this product is exceptional and it is also exported to many world markets. In addition, an array of innovative products developed and commercialized on our patented Platform Technology which includes:
Range of Topical Corticosteroids in a cream matrix of Biochitoderm:
- Hydrocortisone Acetate Cream
- Beclomethasone Dipropionate Cream
- Betamethasone Valerate Cream
- Mometasone Furoate Cream
- Clobetasol Propionate Cream
- Halobetasole Propionate Cream
Combination of Topical corticosteroid with antibacterial agent in a cream matrix of Biochitoderm (Chitosan Biopolymer):
- Mometasone Furoate with Sodium Fusidate Cream
- Beclomethasone Dipropionate with Sodium Fusidate Cream
Combination of Topical corticosteroid with salicylic acid in an ointment base containing Biochitoderm:
- Clobetasol Propionate with salicylic acid ointment
- Halobetasole with salicylic acid ointment
Antibacterial agents in a cream matrix of Biochitoderm:
- Sodium Fusidate Cream
- Silver Sulphadiazine Cream
Antifungal agents in a cream matrix of Biochitoderm:
- Terbinafine Cream
- Clotrimazole Cream
- Miconazole Cream
As part of its new focus, the division’s capability has been enhanced to undertake contract research and technology transfer to pharmaceutical corporations across the globe. This will also include the provision of innovative technology development services to our strategic business partners.
The fundamental driving force of our corporate strategy is to identify therapy gaps in competitive global brands and not only fill up this gap with innovation but also uplift the value delivery to the patients, in terms of care, comfort and speed of recovery to healthy state.